Stifel analyst Bradley Canino raised the firm’s price target on Merus to $45 from $44 and keeps a Buy rating on the shares. The company’s Q2 update included information that the 2/3L HNSCC trial will initiate in mid-2024 and continues development towards a 1L HNSCC trial in combination with Keytruda, the analyst tells investors. Stifel believes Wall Street is more focused on the 1L HNSCC opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRUS:
- Merus price target raised to $48 from $46 at Guggenheim
- Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
- Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
- Merus management to meet virtually with Needham
- Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration